27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
- Becton, Dickinson And Co (NYSE:BDX) has received FDA 510(k) clearance for expanded indications for the Rotarex Atherectomy System.
- Related: BDX Stock Plunges Despite Q3 Earnings Topping Estimates On Recovery In Elective Volumes; Raised FY21 Guidance.
- The Rotarex Atherectomy System is a rotational excisional device built to remove and aspirate varying lesion morphologies, including plaque and thrombus in the peripheral arteries.
- The Rotarex System, already cleared for use in native arterial vessels, now has the expanded indications to treat within peripheral arteries fitted with stents, stent-grafts, and native or artificial bypasses.
- Related content: Benzinga's Full FDA Calendar.
- Price Action: BDX stock closed 1.08% higher at $243.06 on Tuesday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!